{"Clinical Trial ID": "NCT01463007", "Intervention": ["INTERVENTION 1:", "Radiation", "- AccuBoost APBI- 34.0 Gy in 10fx", "\u2022 Accelerating partial breast irradiation: Accubost APBI 34.0 Gy in 10 fractions", "INTERVENTION 2:", "Enlarged up to 5 years of follow-up - Rhode Island Hospital only", "The follow-up was extended to include follow-up visits to 2.6 weeks and 4.6.12.18.24 months, and each year (+/- 6 months) for an additional 3 years for a total of about 5 years of follow-up."], "Eligibility": ["Incorporation criteria:", "A confirmed histological diagnosis of invasive breast carcinoma or DCIS", "Age greater than or equal to 50 years", "Life expectancy > 6 months", "Treatment with breast conservation surgery with axillary dissection or sentinel biopsy of lymph nodes", "- Pathological tumour size of 2 cm or less", "Invasive ductal, mucous, tubular or colloidal histology", "- Positive estrogen receptor for invasive carcinoma.", "One-to-one/unit-centric disease", "- Negative surgical margins greater than or equal to 2 mm", "Negative pathological lymph node", "No evidence of lymphovascular invasion", "ECOG 0 or 1 performance status (Appendix 1)", "Signed informed consent.", "- Exclusion criteria:", "\u2022 Known number BRCA 1/2 Mutation; (BRCA 1 and 2 tests are not required)", "Autoimmune disorders", "Pregnancy", "Breast implants", "A psychiatric or addictive disorder that would prevent participation in follow-up", "- Neoadjuvant chemotherapy (adjuvant chemotherapy is allowed)", "(unless biopsy has proven to be benign)", "Lobular characteristics of histology (pure or mixed) or histology of sarcoma", "A positive node on the axillary dissection or in the sentinel biopsy of the ganglion;", "Large in situ carcinomas (EICs)", "Multicentre or multifocal diseases", "Paget's nipple disease", "\u2022 Remote metastases", "The lumpectomy cavity is not well visualized on AccuBoost imaging", "The lumpectomy cavity with a margin of 1cm (PTV) is not sufficiently covered by an applicator (PTV > 6cm)", "Breast separation with compression > 7cm.", "\u2022 Superposition of the skin between the orthogonal treatment axes."], "Results": ["Performance measures:", "Early and intermediate toxicity", "Any radiological treatment toxicity will be noted and noted using the Common Terminology Criteria for Adverse Events of the National Cancer Institute (NCI) v3.0 (Appendix 4). Acute side effects are all side effects occurring within 3 months of treatment. Intermediate side effects are all side effects occurring between 3 months and 2 years.", "Time limit: 2 years", "Results 1:", "Title of the arm/group: Radiation", "Description of the arm/group: AccuBoost APBI- 34.0 Gy in 10fx", "\u2022 Accelerating partial breast irradiation: Accubost APBI 34.0 Gy in 10 fractions", "Total number of participants analysed: 41", "Type of measurement: Number", "Unit of measure: participants 40", "Results 2:", "Title of the arm/group: Extended to 5 years of follow-up-Rhode Island Hospital Only", "The follow-up was extended to include follow-up visits to 2.6 weeks and 4.6.12.18.24 months, and each year (+/- 6 months) for an additional 3 years for a total of approximately 5 years of follow-up.", "Total number of participants analysed: 28", "Type of measurement: Number", "Unit of measurement: participants 28"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/41 (2.44 per cent)", "Infection 1/41 (2.44 per cent)", "Creatinine 1/41 (2.44 per cent)", "Hypokalaemia 1/41 (2.44%)", "- Bicarbonate 1/41 (2.44%)", "- SGOT 1/41 (2.44%)", "Value of alkaline phosphatase 1/41 (2.44%)", "- Hyperbilirubineamia 1/41 (2.44%)", "Hypoalbuminaemia 1/41 (2.44%)", "- Leukocytes 1/41 (2.44%)", "Hemoglobin 1/41 (2.44%)", "Neutrophils 1/41 (2.44 per cent)", "INR 1/41 (2.44 per cent)", "PTT 1/41 (2.44 per cent)", "Adverse Events 2:", "- Yeah, that's right."]}